Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis Transmembrane Conductance Regulator | 10 | 2013 | 11 | 1.590 |
Why?
|
| Mutation | 10 | 2015 | 97 | 1.210 |
Why?
|
| Cystic Fibrosis | 7 | 2013 | 8 | 1.210 |
Why?
|
| Trypsinogen | 2 | 2011 | 9 | 0.610 |
Why?
|
| Neonatal Screening | 3 | 2013 | 4 | 0.450 |
Why?
|
| Genetic Counseling | 4 | 2015 | 8 | 0.450 |
Why?
|
| Chlorides | 2 | 2013 | 12 | 0.390 |
Why?
|
| Genetic Testing | 5 | 2014 | 50 | 0.380 |
Why?
|
| Sweat | 1 | 2011 | 2 | 0.360 |
Why?
|
| Carrier Proteins | 2 | 2012 | 28 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2015 | 63 | 0.340 |
Why?
|
| Rubinstein-Taybi Syndrome | 1 | 2010 | 1 | 0.330 |
Why?
|
| Crohn Disease | 1 | 2010 | 5 | 0.330 |
Why?
|
| Societies, Medical | 1 | 2009 | 67 | 0.290 |
Why?
|
| Mutation, Missense | 3 | 2013 | 17 | 0.290 |
Why?
|
| DNA Mutational Analysis | 5 | 2011 | 15 | 0.280 |
Why?
|
| Genetic Variation | 6 | 2015 | 40 | 0.270 |
Why?
|
| Humans | 18 | 2015 | 6794 | 0.260 |
Why?
|
| Pancreatitis | 1 | 2006 | 108 | 0.230 |
Why?
|
| Computational Biology | 2 | 2015 | 13 | 0.220 |
Why?
|
| Genetic Carrier Screening | 3 | 2014 | 4 | 0.220 |
Why?
|
| DNA | 3 | 2011 | 39 | 0.200 |
Why?
|
| Infant | 4 | 2013 | 187 | 0.190 |
Why?
|
| Infant, Newborn | 4 | 2013 | 199 | 0.180 |
Why?
|
| Female | 8 | 2014 | 4060 | 0.180 |
Why?
|
| Pancreatitis, Chronic | 2 | 2012 | 69 | 0.170 |
Why?
|
| Male | 7 | 2014 | 3671 | 0.170 |
Why?
|
| Child | 3 | 2010 | 524 | 0.140 |
Why?
|
| Genomics | 1 | 2015 | 13 | 0.120 |
Why?
|
| Software | 1 | 2015 | 18 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2015 | 4 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 84 | 0.120 |
Why?
|
| Jews | 1 | 2014 | 1 | 0.110 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 2 | 0.110 |
Why?
|
| Genotype | 2 | 2011 | 28 | 0.110 |
Why?
|
| Prenatal Diagnosis | 2 | 2013 | 11 | 0.110 |
Why?
|
| California | 2 | 2013 | 230 | 0.110 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2014 | 4 | 0.110 |
Why?
|
| BRCA2 Protein | 1 | 2014 | 12 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2013 | 13 | 0.110 |
Why?
|
| Alleles | 5 | 2014 | 22 | 0.100 |
Why?
|
| Codon | 1 | 2013 | 2 | 0.100 |
Why?
|
| Chymotrypsin | 1 | 2012 | 5 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 170 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 98 | 0.090 |
Why?
|
| Trypsin | 2 | 2012 | 14 | 0.090 |
Why?
|
| Vas Deferens | 2 | 2008 | 2 | 0.090 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 2 | 2012 | 2 | 0.090 |
Why?
|
| Incidence | 1 | 2011 | 197 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2011 | 258 | 0.090 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2010 | 3 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2010 | 17 | 0.080 |
Why?
|
| Gene Frequency | 4 | 2014 | 12 | 0.070 |
Why?
|
| HEK293 Cells | 3 | 2013 | 16 | 0.070 |
Why?
|
| Oligospermia | 2 | 2008 | 3 | 0.070 |
Why?
|
| Adult | 3 | 2014 | 2113 | 0.070 |
Why?
|
| Adolescent | 2 | 2006 | 869 | 0.060 |
Why?
|
| Aged | 2 | 2014 | 1539 | 0.060 |
Why?
|
| Blood Specimen Collection | 1 | 2006 | 5 | 0.060 |
Why?
|
| Acute Disease | 1 | 2006 | 91 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2006 | 167 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2015 | 23 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 112 | 0.050 |
Why?
|
| Infertility, Male | 1 | 2004 | 6 | 0.050 |
Why?
|
| Algorithms | 2 | 2014 | 83 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 43 | 0.040 |
Why?
|
| Heterozygote | 2 | 2010 | 9 | 0.030 |
Why?
|
| Web Browser | 1 | 2015 | 1 | 0.030 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2015 | 1 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 11 | 0.030 |
Why?
|
| Multigene Family | 1 | 2015 | 6 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 8 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 55 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 231 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 3 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 23 | 0.030 |
Why?
|
| Penetrance | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 18 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 28 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2015 | 246 | 0.030 |
Why?
|
| RNA Folding | 1 | 2013 | 1 | 0.030 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 1 | 2013 | 1 | 0.030 |
Why?
|
| Ion Channel Gating | 1 | 2013 | 2 | 0.030 |
Why?
|
| RNA Stability | 1 | 2013 | 3 | 0.030 |
Why?
|
| Action Potentials | 1 | 2013 | 6 | 0.030 |
Why?
|
| Protein Transport | 1 | 2013 | 23 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2013 | 9 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 59 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2013 | 54 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 190 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2012 | 3 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 2 | 0.020 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2012 | 10 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2012 | 9 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 56 | 0.020 |
Why?
|
| Standard of Care | 1 | 2010 | 2 | 0.020 |
Why?
|
| Animals | 1 | 2015 | 1875 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 8 | 0.020 |
Why?
|
| Phenotype | 1 | 2008 | 91 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 599 | 0.020 |
Why?
|
| Middle Aged | 1 | 2014 | 2108 | 0.020 |
Why?
|
| United States | 1 | 2010 | 1019 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2005 | 26 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2004 | 1 | 0.010 |
Why?
|
| Homozygote | 1 | 2004 | 2 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2004 | 331 | 0.010 |
Why?
|